How did ALT's R&D costs trend over the past year?

Altimmune's (stock code ALT) Research and Development (R&D) costs have shown a significant upward trend over the past year, with a cumulative expenditure of $82.23 million by the end of 2024.

|code|Ticker|Name|Date|R&D Expenses|R&D Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|PFE|PFE.N|Pfizer|2024 Q1|2.493E9|-0.47904191616766467|169|
|ALT|ALT.O|Altimmune|2024 Q1|2.1487E7|24.569540263203667|185|
|GILD|GILD.O|Gilead Sciences|2024 Q1|1.52E9|5.044920525224603|185|
|PFE|PFE.N|Pfizer|2024 Q2|2.696E9|1.812688821752266|169|
|ALT|ALT.O|Altimmune|2024 Q2|2.1155E7|59.62423602203275|185|
|GILD|GILD.O|Gilead Sciences|2024 Q2|1.351E9|-3.9800995024875623|185|
|PFE|PFE.N|Pfizer|2024 Q3|2.598E9|-4.16820361490225|169|
|ALT|ALT.O|Altimmune|2024 Q3|1.9803E7|7.6952360234935835|185|
|GILD|GILD.O|Gilead Sciences|2024 Q3|3.145E9|115.85449553877831|185|
|PFE|PFE.N|Pfizer|2024 Q4|3.035E9|7.8152753108348145|169|